Malabsorption Syndrome Treatment Market Size by Treatment, Disease Condition, Region, Industry-Wide Analysis, Competitive Landscape Assessment & Long-Term Forecast to 2029

10.8%
CAGR (2023-2029)
2.09 USD Bn.
Market Size
312
Report Pages
141
Market Tables

Overview

Malabsorption Syndrome Treatment Market size is projected to reach US$ 4.29 Bn. at the end of the forecast period at a CAGR of 10.8%.

Malabsorption Syndrome refers to the number of digestive disorders which occur due to the incapability of an individual to absorb certain nutrients such as fats, proteins, carbohydrates, and vitamins in the intestinal tract. Common disorders associated with malabsorption syndrome include Celiac disease, Cystic fibrosis, Crohn’s disease, lactose intolerance, intestinal inflammation, parasitic diseases, diseases of gall bladder or liver, and prolonged use of antibiotics. Malabsorption leads to weakness, weight loss, and abdominal discomfort. Malabsorption Syndrome Treatment MarketTo know about the Research Methodology :- Request Free Sample Report

Treatment of the malabsorption is directed largely as per the underlying disease or cause. Some of the treatments include antidiarrheal agents, intestinal hormones, anti-inflammatory medications, pancreatic enzymes supplied orally in case of pancreatic insufficiency and dietary modifications.

Malabsorption Syndrome Treatment Market overview:

Increase in the number of people with digestive disorders such as celiac disease, short bowel syndrome, Crohn's disease and other intestinal disorders are expected to drive the market upward. Other key factors such as unmet medical needs, increasing government assistance and rising healthcare expenditure are contributing to the growth of the market.

Despite these drivers, some issues associated with malabsorption market such as side effects of drugs and other therapeutic agents, lack of awareness, and poor healthcare system in developing countries may hamper the growth of the market.

Malabsorption Syndrome Treatment Market Segment Analysis:

According to the segment analysis by disease condition, the Crohn’s disease segment is anticipated to expand during the forecast period due to rapid increase in the number of patients. According to the study published in the Journal of Gastroenterology &Hepatology 2021, inflammatory bowel diseases including Crohn’s disease and ulcerative colitis are relapsing. Currently over 1.5 million people in North America and 2 million people in Europe have inflammatory bowel disease.

Malabsorption Syndrome Treatment Market Regional insights:

According to regional analysis, North America is expected to dominate the global Malabsorption Syndrome treatment market during the forecast period. Owing to the rising cases of causative diseases such as lactose intolerance, diarrhea and cystic fibrosis is expected to drive the market in North America. According to the data published by Cystic Fibrosis Foundation Patient Registry, more than 30,000 individuals are living with cystic fibrosis in the United States and approximately 1000 new cases are diagnosed every year.

Malabsorption Syndrome Treatment Market Scope : Inquire before buying

Global Malabsorption Syndrome Treatment Market
Report Coverage Details
Base Year: 2022 Forecast Period: 2023-2029
Historical Data: 2018 to 2022 Market Size in 2022: US $ 2.09 Bn.
Forecast Period 2023 to 2029 CAGR: 10.8% Market Size in 2029: US $ 4.29 Bn.
Segments Covered: by Treatment Nutritional supplements
Gluten-free diet
Protease and lipase supplements
Antibiotics
Antidiarrheal agents
Anti-inflammatory drugs
Others
by Disease Condition Celiac Disease
Crohn’s Disease
Whipple’s Disease
Short Bowel Syndrome
Intestinal Disorders

Malabsorption Syndrome Treatment Market, by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Malabsorption Syndrome Treatment Market Key Players :

1. GlaxoSmithKline plc.
2. Glenmark pharmaceuticals
3. Abbvie Inc.
4. Actelion pharmaceuticals
5. AstraZeneca plc.
6. Bayer AG
7. Eli Lily and Company
8. Lupin Pharmaceuticals, Inc.
9. Sanofi
10.Pfizer Inc.
11.Hoffmann-La Roche Ltd.
12.Gilead Sciences, Inc.
13.Mallinckrodt pharmaceuticals
14.DSM
15.Klaire laboratories
16.McNeil nutritionals
17.National enzyme company
18.Perrigo
19.VetBiochem India pvt. Ltd.
20.Celgene corporation

Frequently Asked Questions:

1. Which region has the largest share in Global Malabsorption Syndrome Treatment Market?
Ans: North America region held the highest share in 2022.

2. What is the growth rate of Global Malabsorption Syndrome Treatment Market?
Ans: The Global Malabsorption Syndrome Treatment Market is growing at a CAGR of 10.8% during forecasting period 2023-2029.

3. What is scope of the Global Malabsorption Syndrome Treatment market report?
Ans: Global Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global market?
Ans: The important key players in the Global Market are – GlaxoSmithKline plc., Glenmark pharmaceuticals, Abbvie Inc., Actelion pharmaceuticals, AstraZeneca plc., Bayer AG, Eli Lily and Company, Lupin Pharmaceuticals, Inc., Sanofi, Pfizer Inc., Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Mallinckrodt pharmaceuticals, DSM, Klaire laboratories, McNeil nutritionals, National enzyme company, Perrigo, and VetBiochem India pvt. Ltd..

5. What is the study period of this market?
Ans: The Global Market is studied from 2022 to 2029.

Table of Contents

Global Malabsorption Syndrome Treatment Market

1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Malabsorption Syndrome treatment Market Size, by Market Value (US$ Mn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Malabsorption Syndrome treatment Market Analysis and Forecast 6.1. Malabsorption Syndrome treatment Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Malabsorption Syndrome treatment Market Analysis and Forecast, By Treatment 7.1. Introduction and Definition 7.2. Key Findings 7.3. Malabsorption Syndrome treatment Market Value Share Analysis, By Treatment 7.4. Malabsorption Syndrome treatment Market Size (US$ Mn) Forecast, By Treatment 7.5. Malabsorption Syndrome treatment Market Analysis, By Treatment 7.6. Malabsorption Syndrome treatment Market Attractiveness Analysis, By Treatment 8. Global Malabsorption Syndrome treatment Market Analysis and Forecast, By Disease Condition 8.1. Introduction and Definition 8.2. Key Findings 8.3. Malabsorption Syndrome treatment Market Value Share Analysis, By Brake Used 8.4. Malabsorption Syndrome treatment Market Size (US$ Mn) Forecast, By Brake Used 8.5. Malabsorption Syndrome treatment Market Analysis, By Brake Used 8.6. Malabsorption Syndrome treatment Market Attractiveness Analysis, By Brake Used 9. Global Malabsorption Syndrome treatment Market Analysis, by Region 9.1. Malabsorption Syndrome treatment Market Value Share Analysis, by Region 9.2. Malabsorption Syndrome treatment Market Size (US$ Mn) Forecast, by Region 9.3. Malabsorption Syndrome treatment Market Attractiveness Analysis, by Region 10. North America Malabsorption Syndrome treatment Market Analysis 10.1. Key Findings 10.2. North America Malabsorption Syndrome treatment Market Overview 10.3. North America Malabsorption Syndrome treatment Market Value Share Analysis, By Treatment 10.4. North America Malabsorption Syndrome treatment Market Forecast, By Treatment 10.4.1. Nutritional supplements 10.4.2. Gluten-free diet 10.4.3. Protease and lipase supplements 10.4.4. Antibiotics 10.4.5. Antidiarrheal agents 10.4.6. Anti-inflammatory drugs 10.4.7. Others 10.5. North America Malabsorption Syndrome treatment Market Value Share Analysis, By Disease Condition 10.6. North America Malabsorption Syndrome treatment Market Forecast, By Disease Condition 10.6.1. Celiac Disease 10.6.2. Crohn’s Disease 10.6.3. Whipple’s Disease 10.6.4. Short Bowel Syndrome 10.6.5. Intestinal Disorders 10.7. North America Malabsorption Syndrome treatment Market Value Share Analysis, by Country 10.8. North America Malabsorption Syndrome treatment Market Forecast, by Country 10.8.1. U.S. 10.8.2. Canada 10.8.3. Mexico 10.9. North America Malabsorption Syndrome treatment Market Analysis, by Country 10.10. U.S. Malabsorption Syndrome treatment Market Forecast, By Treatment 10.10.1. Nutritional supplements 10.10.2. Gluten-free diet 10.10.3. Protease and lipase supplements 10.10.4. Antibiotics 10.10.5. Antidiarrheal agents 10.10.6. Anti-inflammatory drugs 10.10.7. Others 10.11. U.S. Malabsorption Syndrome treatment Market Forecast, By Disease Condition 10.11.1. Celiac Disease 10.11.2. Crohn’s Disease 10.11.3. Whipple’s Disease 10.11.4. Short Bowel Syndrome 10.11.5. Intestinal Disorders 10.12. Canada Malabsorption Syndrome treatment Market Forecast, By Treatment 10.12.1. Nutritional supplements 10.12.2. Gluten-free diet 10.12.3. Protease and lipase supplements 10.12.4. Antibiotics 10.12.5. Antidiarrheal agents 10.12.6. Anti-inflammatory drugs 10.12.7. Others 10.13. Canada Malabsorption Syndrome treatment Market Forecast, By Disease Condition 10.13.1. Celiac Disease 10.13.2. Crohn’s Disease 10.13.3. Whipple’s Disease 10.13.4. Short Bowel Syndrome 10.13.5. Intestinal Disorders 10.14. Mexico Malabsorption Syndrome treatment Market Forecast, By Treatment 10.14.1. Nutritional supplements 10.14.2. Gluten-free diet 10.14.3. Protease and lipase supplements 10.14.4. Antibiotics 10.14.5. Antidiarrheal agents 10.14.6. Anti-inflammatory drugs 10.14.7. Others 10.15. Mexico Malabsorption Syndrome treatment Market Forecast, By Disease Condition 10.15.1. Celiac Disease 10.15.2. Crohn’s Disease 10.15.3. Whipple’s Disease 10.15.4. Short Bowel Syndrome 10.15.5. Intestinal Disorders 10.16. North America Malabsorption Syndrome treatment Market Attractiveness Analysis 10.16.1. By Treatment 10.16.2. By Disease Condition 10.17. PEST Analysis 10.18. Key Trends 10.19. Key Developments 11. Europe Malabsorption Syndrome treatment Market Analysis 11.1. Key Findings 11.2. Europe Malabsorption Syndrome treatment Market Overview 11.3. Europe Malabsorption Syndrome treatment Market Value Share Analysis, By Treatment 11.4. Europe Malabsorption Syndrome treatment Market Forecast, By Treatment 11.4.1. Nutritional supplements 11.4.2. Gluten-free diet 11.4.3. Protease and lipase supplements 11.4.4. Antibiotics 11.4.5. Antidiarrheal agents 11.4.6. Anti-inflammatory drugs 11.4.7. Others 11.5. Europe Malabsorption Syndrome treatment Market Forecast, By Disease Condition 11.5.1. Celiac Disease 11.5.2. Crohn’s Disease 11.5.3. Whipple’s Disease 11.5.4. Short Bowel Syndrome 11.5.5. Intestinal Disorders 11.6. Europe Malabsorption Syndrome treatment Market Value Share Analysis, by Country 11.7. Europe Malabsorption Syndrome treatment Market Forecast, by Country 11.7.1. Germany 11.7.2. U.K. 11.7.3. France 11.7.4. Italy 11.7.5. Spain 11.7.6. Sweden 11.7.7. CIS countries 11.7.8. Rest of Europe 11.8. Germany Malabsorption Syndrome treatment Market Forecast, By Treatment 11.8.1. Nutritional supplements 11.8.2. Gluten-free diet 11.8.3. Protease and lipase supplements 11.8.4. Antibiotics 11.8.5. Antidiarrheal agents 11.8.6. Anti-inflammatory drugs 11.8.7. Others 11.9. Germany Malabsorption Syndrome treatment Market Forecast, By Disease Condition 11.9.1. Celiac Disease 11.9.2. Crohn’s Disease 11.9.3. Whipple’s Disease 11.9.4. Short Bowel Syndrome 11.9.5. Intestinal Disorders 11.10. U.K. Malabsorption Syndrome treatment Market Forecast, By Treatment 11.10.1. Nutritional supplements 11.10.2. Gluten-free diet 11.10.3. Protease and lipase supplements 11.10.4. Antibiotics 11.10.5. Antidiarrheal agents 11.10.6. Anti-inflammatory drugs 11.10.7. Others 11.11. U.K. Malabsorption Syndrome treatment Market Forecast, By Disease Condition 11.11.1. Celiac Disease 11.11.2. Crohn’s Disease 11.11.3. Whipple’s Disease 11.11.4. Short Bowel Syndrome 11.11.5. Intestinal Disorders 11.12. France Malabsorption Syndrome treatment Market Forecast, By Treatment 11.12.1. Nutritional supplements 11.12.2. Gluten-free diet 11.12.3. Protease and lipase supplements 11.12.4. Antibiotics 11.12.5. Antidiarrheal agents 11.12.6. Anti-inflammatory drugs 11.12.7. Others 11.13. France Malabsorption Syndrome treatment Market Forecast, By Disease Condition 11.13.1. Celiac Disease 11.13.2. Crohn’s Disease 11.13.3. Whipple’s Disease 11.13.4. Short Bowel Syndrome 11.13.5. Intestinal Disorders 11.14. Italy Malabsorption Syndrome treatment Market Forecast, By Treatment 11.14.1. Nutritional supplements 11.14.2. Gluten-free diet 11.14.3. Protease and lipase supplements 11.14.4. Antibiotics 11.14.5. Antidiarrheal agents 11.14.6. Anti-inflammatory drugs 11.14.7. Others 11.15. Italy Malabsorption Syndrome treatment Market Forecast, By Disease Condition 11.15.1. Celiac Disease 11.15.2. Crohn’s Disease 11.15.3. Whipple’s Disease 11.15.4. Short Bowel Syndrome 11.15.5. Intestinal Disorders 11.16. Spain Malabsorption Syndrome treatment Market Forecast, By Treatment 11.16.1. Nutritional supplements 11.16.2. Gluten-free diet 11.16.3. Protease and lipase supplements 11.16.4. Antibiotics 11.16.5. Antidiarrheal agents 11.16.6. Anti-inflammatory drugs 11.16.7. Others 11.17. Spain Malabsorption Syndrome treatment Market Forecast, By Disease Condition 11.17.1. Celiac Disease 11.17.2. Crohn’s Disease 11.17.3. Whipple’s Disease 11.17.4. Short Bowel Syndrome 11.17.5. Intestinal Disorders 11.18. Sweden Malabsorption Syndrome treatment Market Forecast, By Treatment 11.18.1. Nutritional supplements 11.18.2. Gluten-free diet 11.18.3. Protease and lipase supplements 11.18.4. Antibiotics 11.18.5. Antidiarrheal agents 11.18.6. Anti-inflammatory drugs 11.18.7. Others 11.19. Sweden Malabsorption Syndrome treatment Market Forecast, By Disease Condition 11.19.1. Celiac Disease 11.19.2. Crohn’s Disease 11.19.3. Whipple’s Disease 11.19.4. Short Bowel Syndrome 11.19.5. Intestinal Disorders 11.20. CIS countries Malabsorption Syndrome treatment Market Forecast, By Treatment 11.20.1. Nutritional supplements 11.20.2. Gluten-free diet 11.20.3. Protease and lipase supplements 11.20.4. Antibiotics 11.20.5. Antidiarrheal agents 11.20.6. Anti-inflammatory drugs 11.20.7. Others 11.21. CIS countries Malabsorption Syndrome treatment Market Forecast, By Disease Condition 11.21.1. Celiac Disease 11.21.2. Crohn’s Disease 11.21.3. Whipple’s Disease 11.21.4. Short Bowel Syndrome 11.21.5. Intestinal Disorders 11.22. Rest of Europe Malabsorption Syndrome treatment Market Forecast, By Treatment 11.22.1. Nutritional supplements 11.22.2. Gluten-free diet 11.22.3. Protease and lipase supplements 11.22.4. Antibiotics 11.22.5. Antidiarrheal agents 11.22.6. Anti-inflammatory drugs 11.22.7. Others 11.23. Rest of Europe Malabsorption Syndrome treatment Market Forecast, By Disease Condition 11.23.1. Celiac Disease 11.23.2. Crohn’s Disease 11.23.3. Whipple’s Disease 11.23.4. Short Bowel Syndrome 11.23.5. Intestinal Disorders 11.24. Europe Malabsorption Syndrome treatment Market Attractiveness Analysis 11.24.1. By Disease Condition 11.24.2. By Treatment 11.25. PEST Analysis 11.26. Key Trends 11.27. Key Developments 12. Asia Pacific Malabsorption Syndrome treatment Market Analysis 12.1. Key Findings 12.2. Asia Pacific Malabsorption Syndrome treatment Market Overview 12.3. Asia Pacific Malabsorption Syndrome treatment Market Value Share Analysis, By Treatment 12.4. Asia Pacific Malabsorption Syndrome treatment Market Forecast, By Treatment 12.4.1. Nutritional supplements 12.4.2. Gluten-free diet 12.4.3. Protease and lipase supplements 12.4.4. Antibiotics 12.4.5. Antidiarrheal agents 12.4.6. Anti-inflammatory drugs 12.4.7. Others 12.5. Asia Pacific Malabsorption Syndrome treatment Market Value Share Analysis, By Treatment 12.6. Asia Pacific Malabsorption Syndrome treatment Market Forecast, By Disease Condition 12.6.1. Celiac Disease 12.6.2. Crohn’s Disease 12.6.3. Whipple’s Disease 12.6.4. Short Bowel Syndrome 12.6.5. Intestinal Disorders 12.7. Asia Pacific Malabsorption Syndrome treatment Market Value Share Analysis, by Country 12.8. Asia Pacific Malabsorption Syndrome treatment Market Forecast, by Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. South Korea 12.8.5. Australia 12.8.6. ASEAN 12.8.7. Rest of Asia Pacific 12.9. Asia Pacific Malabsorption Syndrome treatment Market Analysis, by Country 12.10. China Malabsorption Syndrome treatment Market Forecast, By Treatment 12.10.1. Nutritional supplements 12.10.2. Gluten-free diet 12.10.3. Protease and lipase supplements 12.10.4. Antibiotics 12.10.5. Antidiarrheal agents 12.10.6. Anti-inflammatory drugs 12.10.7. Others 12.11. China Malabsorption Syndrome treatment Market Forecast, By Disease Condition 12.11.1. Celiac Disease 12.11.2. Crohn’s Disease 12.11.3. Whipple’s Disease 12.11.4. Short Bowel Syndrome 12.11.5. Intestinal Disorders 12.12. India Malabsorption Syndrome treatment Market Forecast, By Treatment 12.12.1. Nutritional supplements 12.12.2. Gluten-free diet 12.12.3. Protease and lipase supplements 12.12.4. Antibiotics 12.12.5. Antidiarrheal agents 12.12.6. Anti-inflammatory drugs 12.12.7. Others 12.13. India Malabsorption Syndrome treatment Market Forecast, By Disease Condition 12.13.1. Celiac Disease 12.13.2. Crohn’s Disease 12.13.3. Whipple’s Disease 12.13.4. Short Bowel Syndrome 12.13.5. Intestinal Disorders 12.14. Japan Malabsorption Syndrome treatment Market Forecast, By Treatment 12.14.1. Nutritional supplements 12.14.2. Gluten-free diet 12.14.3. Protease and lipase supplements 12.14.4. Antibiotics 12.14.5. Antidiarrheal agents 12.14.6. Anti-inflammatory drugs 12.14.7. Others 12.15. Japan Malabsorption Syndrome treatment Market Forecast, By Disease Condition 12.15.1. Celiac Disease 12.15.2. Crohn’s Disease 12.15.3. Whipple’s Disease 12.15.4. Short Bowel Syndrome 12.15.5. Intestinal Disorders 12.16. South Korea Malabsorption Syndrome treatment Market Forecast, By Treatment 12.16.1. Nutritional supplements 12.16.2. Gluten-free diet 12.16.3. Protease and lipase supplements 12.16.4. Antibiotics 12.16.5. Antidiarrheal agents 12.16.6. Anti-inflammatory drugs 12.16.7. Others 12.17. South Korea Malabsorption Syndrome treatment Market Forecast, By Disease Condition 12.17.1. Celiac Disease 12.17.2. Crohn’s Disease 12.17.3. Whipple’s Disease 12.17.4. Short Bowel Syndrome 12.17.5. Intestinal Disorders 12.18. Australia Malabsorption Syndrome treatment Market Forecast, By Treatment 12.18.1. Nutritional supplements 12.18.2. Gluten-free diet 12.18.3. Protease and lipase supplements 12.18.4. Antibiotics 12.18.5. Antidiarrheal agents 12.18.6. Anti-inflammatory drugs 12.18.7. Others 12.19. Australia Malabsorption Syndrome treatment Market Forecast, By Disease Condition 12.19.1. Celiac Disease 12.19.2. Crohn’s Disease 12.19.3. Whipple’s Disease 12.19.4. Short Bowel Syndrome 12.19.5. Intestinal Disorders 12.20. ASEAN Malabsorption Syndrome treatment Market Forecast, By Treatment 12.20.1. Nutritional supplements 12.20.2. Gluten-free diet 12.20.3. Protease and lipase supplements 12.20.4. Antibiotics 12.20.5. Antidiarrheal agents 12.20.6. Anti-inflammatory drugs 12.20.7. Others 12.21. ASEAN Malabsorption Syndrome treatment Market Forecast, By Disease Condition 12.21.1. Celiac Disease 12.21.2. Crohn’s Disease 12.21.3. Whipple’s Disease 12.21.4. Short Bowel Syndrome 12.21.5. Intestinal Disorders 12.22. Rest of Asia Pacific Malabsorption Syndrome treatment Market Forecast, By Treatment 12.22.1. Nutritional supplements 12.22.2. Gluten-free diet 12.22.3. Protease and lipase supplements 12.22.4. Antibiotics 12.22.5. Antidiarrheal agents 12.22.6. Anti-inflammatory drugs 12.22.7. Others 12.23. Rest of Asia Pacific Malabsorption Syndrome treatment Market Forecast, By Disease Condition 12.23.1. Celiac Disease 12.23.2. Crohn’s Disease 12.23.3. Whipple’s Disease 12.23.4. Short Bowel Syndrome 12.23.5. Intestinal Disorders 12.24. Asia Pacific Malabsorption Syndrome treatment Market Attractiveness Analysis 12.24.1. By Treatment 12.24.2. By Disease Condition 12.25. PEST Analysis 12.26. Key Trends 12.27. Key Developments 13. Middle East & Africa Malabsorption Syndrome treatment Market Analysis 13.1. Key Findings 13.2. Middle East & Africa Malabsorption Syndrome treatment Market Overview 13.3. Middle East & Africa Malabsorption Syndrome treatment Market Value Share Analysis, By Treatment 13.4. Middle East & Africa Malabsorption Syndrome treatment Market Forecast, By Treatment 13.4.1. Nutritional supplements 13.4.2. Gluten-free diet 13.4.3. Protease and lipase supplements 13.4.4. Antibiotics 13.4.5. Antidiarrheal agents 13.4.6. Anti-inflammatory drugs 13.4.7. Others 13.5. Middle East & Africa Malabsorption Syndrome treatment Market Forecast, By Disease Condition 13.5.1. Celiac Disease 13.5.2. Crohn’s Disease 13.5.3. Whipple’s Disease 13.5.4. Short Bowel Syndrome 13.5.5. Intestinal Disorders 13.6. Middle East & Africa Malabsorption Syndrome treatment Market Value Share Analysis, by Country 13.7. Middle East & Africa Malabsorption Syndrome treatment Market Forecast, by Country 13.7.1. GCC Countries 13.7.2. South Africa 13.7.3. Nigeria 13.7.4. Egypt 13.7.5. Rest of Middle East & Africa 13.8. Middle East & Africa Malabsorption Syndrome treatment Market Analysis, by Country 13.9. GCC Countries Malabsorption Syndrome treatment Market Forecast, By Treatment 13.9.1. Nutritional supplements 13.9.2. Gluten-free diet 13.9.3. Protease and lipase supplements 13.9.4. Antibiotics 13.9.5. Antidiarrheal agents 13.9.6. Anti-inflammatory drugs 13.9.7. Others 13.10. GCC Countries Malabsorption Syndrome treatment Market Forecast, By Disease Condition 13.10.1. Celiac Disease 13.10.2. Crohn’s Disease 13.10.3. Whipple’s Disease 13.10.4. Short Bowel Syndrome 13.10.5. Intestinal Disorders 13.11. South Africa Malabsorption Syndrome treatment Market Forecast, By Treatment 13.11.1. Nutritional supplements 13.11.2. Gluten-free diet 13.11.3. Protease and lipase supplements 13.11.4. Antibiotics 13.11.5. Antidiarrheal agents 13.11.6. Anti-inflammatory drugs 13.11.7. Others 13.12. South Africa Malabsorption Syndrome treatment Market Forecast, By Disease Condition 13.12.1. Celiac Disease 13.12.2. Crohn’s Disease 13.12.3. Whipple’s Disease 13.12.4. Short Bowel Syndrome 13.12.5. Intestinal Disorders 13.13. Nigeria Malabsorption Syndrome treatment Market Forecast, By Treatment 13.13.1. Nutritional supplements 13.13.2. Gluten-free diet 13.13.3. Protease and lipase supplements 13.13.4. Antibiotics 13.13.5. Antidiarrheal agents 13.13.6. Anti-inflammatory drugs 13.13.7. Others 13.14. Nigeria Malabsorption Syndrome treatment Market Forecast, By Disease Condition 13.14.1. Celiac Disease 13.14.2. Crohn’s Disease 13.14.3. Whipple’s Disease 13.14.4. Short Bowel Syndrome 13.14.5. Intestinal Disorders 13.15. Egypt Malabsorption Syndrome treatment Market Forecast, By Treatment 13.15.1. Nutritional supplements 13.15.2. Gluten-free diet 13.15.3. Protease and lipase supplements 13.15.4. Antibiotics 13.15.5. Antidiarrheal agents 13.15.6. Anti-inflammatory drugs 13.15.7. Others 13.16. Egypt Malabsorption Syndrome treatment Market Forecast, By Disease Condition 13.16.1. Celiac Disease 13.16.2. Crohn’s Disease 13.16.3. Whipple’s Disease 13.16.4. Short Bowel Syndrome 13.16.5. Intestinal Disorders 13.17. Rest of Middle East & Africa Malabsorption Syndrome treatment Market Forecast, By Treatment 13.17.1. Nutritional supplements 13.17.2. Gluten-free diet 13.17.3. Protease and lipase supplements 13.17.4. Antibiotics 13.17.5. Antidiarrheal agents 13.17.6. Anti-inflammatory drugs 13.17.7. Others 13.18. Rest of Middle East & Africa Malabsorption Syndrome treatment Market Forecast, By Disease Condition 13.18.1. Celiac Disease 13.18.2. Crohn’s Disease 13.18.3. Whipple’s Disease 13.18.4. Short Bowel Syndrome 13.18.5. Intestinal Disorders 13.19. Middle East & Africa Malabsorption Syndrome treatment MarketAttractiveness Analysis 13.19.1. By Treatment 13.19.2. By Disease Condition 13.20. PEST Analysis 13.21. Key Trends 13.22. Key Developments 14. South America Malabsorption Syndrome treatment Market Analysis 14.1. Key Findings 14.2. South America Malabsorption Syndrome treatment MarketOverview 14.3. South America Malabsorption Syndrome treatment Market Value Share Analysis, By Treatment 14.4. South America Malabsorption Syndrome treatment Market Forecast, By Treatment 14.4.1. Nutritional supplements 14.4.2. Gluten-free diet 14.4.3. Protease and lipase supplements 14.4.4. Antibiotics 14.4.5. Antidiarrheal agents 14.4.6. Anti-inflammatory drugs 14.4.7. Others 14.5. South America Malabsorption Syndrome treatment Market Forecast, By Disease Condition 14.5.1. Celiac Disease 14.5.2. Crohn’s Disease 14.5.3. Whipple’s Disease 14.5.4. Short Bowel Syndrome 14.5.5. Intestinal Disorders 14.6. South America Malabsorption Syndrome treatment Market Value Share Analysis, by Country 14.7. South America Malabsorption Syndrome treatment Market Forecast, by Country 14.7.1. Brazil 14.7.2. Colombia 14.7.3. Argentina 14.7.4. Rest of South America 14.8. South America Malabsorption Syndrome treatment Market Analysis, by Country 14.9. Brazil Malabsorption Syndrome treatment Market Forecast, By Treatment 14.9.1. Nutritional supplements 14.9.2. Gluten-free diet 14.9.3. Protease and lipase supplements 14.9.4. Antibiotics 14.9.5. Antidiarrheal agents 14.9.6. Anti-inflammatory drugs 14.9.7. Others 14.10. Brazil Malabsorption Syndrome treatment Market Forecast, By Disease Condition 14.10.1. Celiac Disease 14.10.2. Crohn’s Disease 14.10.3. Whipple’s Disease 14.10.4. Short Bowel Syndrome 14.10.5. Intestinal Disorders 14.11. Colombia Malabsorption Syndrome treatment Market Forecast, By Treatment 14.11.1. Nutritional supplements 14.11.2. Gluten-free diet 14.11.3. Protease and lipase supplements 14.11.4. Antibiotics 14.11.5. Antidiarrheal agents 14.11.6. Anti-inflammatory drugs 14.11.7. Others 14.12. Colombia Malabsorption Syndrome treatment Market Forecast, By Disease Condition 14.12.1. Celiac Disease 14.12.2. Crohn’s Disease 14.12.3. Whipple’s Disease 14.12.4. Short Bowel Syndrome 14.12.5. Intestinal Disorders 14.13. Argentina Malabsorption Syndrome treatment Market Forecast, By Treatment 14.13.1. Nutritional supplements 14.13.2. Gluten-free diet 14.13.3. Protease and lipase supplements 14.13.4. Antibiotics 14.13.5. Antidiarrheal agents 14.13.6. Anti-inflammatory drugs 14.13.7. Others 14.14. Argentina Malabsorption Syndrome treatment Market Forecast, By Disease Condition 14.14.1. Celiac Disease 14.14.2. Crohn’s Disease 14.14.3. Whipple’s Disease 14.14.4. Short Bowel Syndrome 14.14.5. Intestinal Disorders 14.15. Rest of South America Malabsorption Syndrome treatment Market Forecast, By Treatment 14.15.1. Nutritional supplements 14.15.2. Gluten-free diet 14.15.3. Protease and lipase supplements 14.15.4. Antibiotics 14.15.5. Antidiarrheal agents 14.15.6. Anti-inflammatory drugs 14.15.7. Others 14.16. Rest of South America Malabsorption Syndrome treatment Market Forecast, By Disease Condition 14.16.1. Celiac Disease 14.16.2. Crohn’s Disease 14.16.3. Whipple’s Disease 14.16.4. Short Bowel Syndrome 14.16.5. Intestinal Disorders 14.17. South America Malabsorption Syndrome treatment Market Attractiveness Analysis 14.17.1. By Treatment 14.17.2. By Disease Condition 14.18. PEST Analysis 14.19. Key Trends 14.20. Key Developments 15. Company Profiles 15.1. Market Share Analysis, by Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications, and R&D investment 15.2.2. New Product Launches and Product Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A by Regions, Investment and Applications 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. GlaxoSmithKline plc. 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Product Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Development Footprint 15.3.2. Glenmark pharmaceuticals 15.3.3. Abbvie Inc. 15.3.4. Actelion pharmaceuticals 15.3.5. AstraZeneca plc. 15.3.6. Bayer AG 15.3.7. Eli Lily and Company 15.3.8. Lupin Pharmaceuticals, Inc. 15.3.9. Sanofi 15.3.10. Pfizer Inc. 15.3.11. Hoffmann-La Roche Ltd. 15.3.12. Gilead Sciences, Inc. 15.3.13. Mallinckrodt pharmaceuticals 15.3.14. DSM 15.3.15. Klaire laboratories 15.3.16. McNeil nutritionals 15.3.17. National enzyme company 15.3.18. Perrigo 15.3.19. VetBiochem India pvt. Ltd. 15.3.20. Celgene corporation 16. Primary key Insights